Rich Aldrich

Mr. Aldrich has been a member of Renovia’s Board since April 2017. Mr. Aldrich is co-founder and General Partner of Longwood Fund and has spent approximately 35 years as a life sciences entrepreneur and investor. Mr. Aldrich co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (Nasdaq: SIRT acquired by GSK in 2008), Concert Pharmaceuticals (Nasdaq: CNCE), where he serves as Chair of the Board, and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (Nasdaq: VSTM), Axial Therapeutics, and TScan Therapeutics. Rich also serves as a Director of Longwood portfolio companies Axial, Sitryx Therapeutics, and Colorescience.

Prior to co-founding Longwood, Mr. Aldrich founded RA Capital Management, LLC, a life sciences investment fund, in which he remains an investor. Prior to founding RA Capital Management, LLC, Mr. Aldrich was a founding employee of Vertex Pharmaceuticals (Nasdaq: VRTX), where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc.

Mr. Aldrich received his undergraduate degree from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College.